Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Javier Bolaños‐Meade(Johns Hopkins University), Sonali M. Smith(University of Chicago), Marcie Riches(Medical College of Wisconsin), Siddhartha Ganguly(University of Kansas Medical Center), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Shimon Slavin, Saurabh Chhabra(Medical College of Wisconsin), Amer Beitinjaneh(University of Miami), Rachel B. Salit(Johns Hopkins Hospital), Hillard M. Lazarus(University Hospitals of Cleveland), César O. Freytes(CHRISTUS Transplant Institute), Alessandro Digilio, Philippe Armand(Harvard University), Alberto Mussetti(Duran i Reynals Hospital), Timothy S. Fenske(Medical College of Wisconsin), Mark Hertzberg(The University of Sydney), Andrew R. Rezvani(Stanford Blood Center), Richard F. Olsson(AstraZeneca (Netherlands)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Evgeny Klyuchnikov(Universität Hamburg), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert Peter Gale(Imperial College London), Jean A. Yared(University of Maryland, Baltimore), Stefan O. Ciurea(University of California, Irvine), Kwang Woo Ahn(Medical College of Wisconsin)
Cited by 273
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k